AIM: To determine whether serum interleukin-18 (IL-18) levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC). METHODS:SerumIL-18, IL-6 and IL-12 levels were measured by enzyme-linked immunosorbent assay (ELISA) from 70 patients with HCC and 10 healthy controls. RESULTS:SerumIL-18, IL-6 and IL-12 levels of patients with HCC were significantly higher that those of the controls. The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages classified by Okuda's criteria. Patients with high serum IL-18 levels (>= 10(5) pg/mL) had a poorer survival than those with low serum IL-18 levels (< 10(5) pg/mL) (4 and 11 mo, respectively, P = 0.015). Multivariate analyses showed that serum IL-18 level, but not IL-6 and IL-12 levels, was a significant and independent prognostic factor of survival. CONCLUSION: These findings demonstrate that serum IL-8 may a useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC. Thus, the detailed mechanisms of IL-18 involving in tumor progression should be further investigated.
RCT Entities:
AIM: To determine whether serum interleukin-18 (IL-18) levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC). METHODS: Serum IL-18, IL-6 and IL-12 levels were measured by enzyme-linked immunosorbent assay (ELISA) from 70 patients with HCC and 10 healthy controls. RESULTS: Serum IL-18, IL-6 and IL-12 levels of patients with HCC were significantly higher that those of the controls. The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages classified by Okuda's criteria. Patients with high serum IL-18 levels (>= 10(5) pg/mL) had a poorer survival than those with low serum IL-18 levels (< 10(5) pg/mL) (4 and 11 mo, respectively, P = 0.015). Multivariate analyses showed that serum IL-18 level, but not IL-6 and IL-12 levels, was a significant and independent prognostic factor of survival. CONCLUSION: These findings demonstrate that serum IL-8 may a useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC. Thus, the detailed mechanisms of IL-18 involving in tumor progression should be further investigated.
Authors: J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko Journal: Cancer Res Date: 1992-06-15 Impact factor: 12.701
Authors: R Parasole; F Izzo; F Perrone; S Pignata; M G Galati; E Leonardi; F Castiglione; R Orlando; G Castello; G Esposito; C Gallo; B Daniele Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: G Scambia; U Testa; P Benedetti Panici; E Foti; R Martucci; A Gadducci; A Perillo; V Facchini; C Peschle; S Mancuso Journal: Br J Cancer Date: 1995-02 Impact factor: 7.640
Authors: Hendrik W van Deventer; Joseph E Burgents; Qing Ping Wu; Rita-Marie T Woodford; W June Brickey; Irving C Allen; Erin McElvania-Tekippe; Jonathan S Serody; Jenny P-Y Ting Journal: Cancer Res Date: 2010-12-15 Impact factor: 12.701